

Figure S1. Etanercept attenuates caerulein-induced ROS production. (A) Caerulein (10 nmol/l) induced ROS accumulation in H19-7/IGF-IR cells treated with 0 μ mol/ml etanercept by flow cytometry (n=3). (B) Caerulein (10 nmol/l) induced ROS accumulation in H19-7/IGF-IR cells treated with 1 μ mol/ml etanercept by flow cytometry (n=3). (C) Caerulein (10 nmol/l) induced ROS accumulation in H19-7/IGF-IR cells treated with 10 μ mol/ml etanercept by flow cytometry (n=3). (D) Caerulein (10 nmol/l) induced ROS accumulation in H19-7/IGF-IR cells treated with 100 μ mol/ml etanercept by flow cytometry (n=3). (E) Etanercept dose-dependently decreased caerulein-induced ROS accumulation (n=3). * P <0.05 vs. group without etanercept. ROS, reactive oxygen species; EP, etanercept.

